key note session at bangalore india bio on actualizing potential of clinical trials
DESCRIPTION
Accelerating Pharma time-to-market, cost effectively. Asia. Europe. Americas. Key note session at Bangalore India BIO on Actualizing Potential of Clinical Trials June 4 th 2010 D A Prasanna Founder & Vice Chairman Ecron Acunova. introduction. - PowerPoint PPT PresentationTRANSCRIPT
1
Key note session at Bangalore India BIO on
Actualizing Potential of Clinical TrialsJune 4th 2010
D A PrasannaFounder & Vice Chairman Ecron Acunova
Asia Europe Americas
Accelerating Pharma time-to-market, cost effectively
introduction
2
EA combines domain knowledge, patient access & financial strength
Leveraging India, Central & Eastern Europe for speed & cost
Highlights
• Recruited 17,000+ patients last 5 years• Full service I-IV, CDM, Central Lab, PK/PD• Oncology, CV, Metabolic, Respiratory• Lead in stem cell & diagnostic agent trails• Studies found compliant by US FDA, HC, WHO, DCGI etc.
Ranks amongst top 3 Indian Clinical Research Organization forQuality, Revenue and Reputation
India in Clinical trial so far…
3
India is engaged in clinical research for the last 15 years. Starting with
•size of population•English in communication•disease burden•naïve patient advantage•western medical education
We have coveted a position of interest in the minds of clinical development community.
Yet India’s share has not become significant. What are some steps required to get a higher leverage of our potential?
4
Clinical Trial India‘s relative position
IN 1232PO 1714
30th November 2009, clinicaltrials.gov
No of sites 08 ROW (w/o US)DE 7825 16,9%
FR 6047 13,1%
UK 3762 8,1%
ES 3550 7,7%
IT 3300 7,1%
JP 2707 5,9%
PL 2328 5,0%
RU 2277 4,9%
AUS 1952 4,2%
BE 1900 4,1%
NL 1650 3,6%
SW 1440 3,1%
HU 1326 2,9%
CZ 1311 2,8%
AR 1310 2,8%
IN 1256 2,7%
BR 1256 2,7%
AT 1000 2,2%No of registered clinical trials
5
Foreign data acceptance by US, EU
FDA’s acceptance of foreign clinical trial data:• GCP compliance• Investigators of recognized competence• Valid Scientific evidence• Applicable to US population / medical practice
ICH E5 and 21 CFR 312.120 articulate the principles
Therapy area competence
6
Special experiences and knowledge in clinical studies in oncology field:
Special in- and exclusion criteria, histological results TNM Staging (Tumor, Lymph nodes, Metastasis) Special physical examinations, e.g. ECOG / Karnofsky-Index Tumor evaluation (RECIST) Cooperation with radiologists Preparation of infusion Cooperation with pharmacists Evaluation of laboratory results that are specially influenced by
chemotherapy (hematological values) Assessment of special tumor markers Side effects of chemotherapy / new chemotherapies Side effects with other medication AEs of special interests (drug related) SD check Special documentation of source data
Expertise contributes to data quality
Graduate from Ph III
7
Early years: Registration trials Ph IV
Last decade: Ph III global trials
This decade: Add Ph Ib to Ph II
Early development for top 20 Pharma calls for new Competency
•PK/PD studies (insulin clamp study for eg)
•cadre of drug safety specialists.
•Sites with safety preparedness
Doing a Ph II improves likelihood of Ph III
Breadth of expertise
8
In a therapy area, research breadth from
•drug delivery devices•Co-morbidity •nutritional research•life style management•Devices
Helps to leverage same sites and bring perspectives
Qualify & support infrastructure
A. Conventional infrastructure– Trained investigators
– Accredited study coordinators
– Investigator networks
B. Special infrastructure– Drug labeling in stem cells
– Stem cell EC
– Core lab in spirometry for respiratory
– Special biomarker testing
– Trials involving PET agent with less than one day half life
– Blinded readers
9
Building an ecosystem and qualifying improves quality
Credible regulatory bodies
• Investigator meeting coming under MCI scanner for inducement of Physicians
• Ph IV trials seeding a new variant or collection of new scientific data?
• Requirement of clinical trial a qualitative trade barrier?
• DCGI ‘s collaboration with US FDA and Health Canada is a great step
10
From National to Regional CRO
• Last decade National expert CRO’s in demand• This decade many sponsors are reducing number of service
providers• Service providers also need to align
– Regional or transnational
– Follow disease burden map in geography expansion!
11
As a country we can participate in larger programs
In summary
• Foreign patient inclusion – understand to get the right trial to India
• Build therapy area competence in CRO’s• Extend to early development studies• Cover the breadth of a therapy area & leverage sites• Build an eco system for clinical trials• Credibility of regulatory bodies• Align with changing sourcing strategy of sponsors
12
Thanks
• Ecron Acunova team in educating me for this talk• India BIO for the platform• Attendees for your attention
13
Contact us www.ecronacunova.com We accelerate Pharma time-to-market cost effectively
ASIA EUROPE AMERICAS
SJR I Park, Mobius EPIP, Whitefield Bangalore – 560 066India
+91 80 6691 5725
Hahnstrasse 70D-60528 FrankfurtGermany
+49 69 6680300
502 Carnegie Center Suite # 100 Princeton NJ 08540, USA
+1 973 396 2742
Full ServiceCRO
20+Y E A R S
Track Record